| Nov 11 |
Zai Lab and argenx Announce Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in China
|
| Oct 30 |
Zai Lab presents positive outcomes from KarXT Phase III trial for schizophrenia
|
| Oct 29 |
Zai Lab reports positive Chinese study data for KarXT for schizophrenia
|
| Oct 29 |
Zai Lab Reports Positive Topline Data from Phase 3 Bridging Trial Evaluating KarXT for the Treatment of Schizophrenia in China
|
| Oct 28 |
High Growth Tech Stocks In The United States With Promising Potential
|
| Oct 25 |
Zai Lab Limited (ZLAB) Moves 14.7% Higher: Will This Strength Last?
|
| Oct 24 |
Zai Lab, A Top 6% Stock, Launched To A 16-Month High On Its 'Impressive' Results
|
| Oct 24 |
Zai Lab stock rockets 24% on data for lung cancer ADC drug
|
| Oct 24 |
ZL-1310, an Investigational DLL3-Targeted Antibody-Drug Conjugate (ADC), Demonstrates Promising Objective Response Rates and Safety Profile in Extensive-Stage Small Cell Lung Cancer
|
| Oct 18 |
Zai Lab Announces Participation in November and December Investor Conferences
|
